Research summary
Research HubGHRP-6
Clinical — 10 studies
GHRP-6 is a growth hormone–releasing peptide studied for GH stimulation and appetite-related ghrelin signaling.
Being studied for
- GH secretion research
- Ghrelin receptor signaling
Published Research
Evidence profile
Human Phase 1 evidence
10 cited publications · 6 primary trials
Findings below belong to the studies that reported them. They describe the material and conditions those authors used, not this product, and not an outcome to expect.
Supporting evidence
Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers
Cabrales A et al. · European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2013
The study reportedDose dependence analysis revealed a noticeable trend for AUC to increase proportionally with administered dose. Atypical GHRP-6 concentration spikes were observed during the elimination phase in four out of the nine subjects studied.
Effects of ghrelin, GH-releasing peptide-6 (GHRP-6) and GHRH on GH, ACTH and cortisol release in hyperthyroidism before and after treatment
Molica P et al. · Pituitary · 2010
The study reportedOur results suggest that the pathways of GH release after ghrelin/GHRP-6 and GHRH are similarly affected by thyroid hormone excess and hypothalamic mechanisms of ACTH release modulated by ghrelin/GHSs may be activated in this situation.
Growth hormone responses to GH-releasing peptide (GHRP-6) in hypothyroidism
Pimentel-Filho FR et al. · Clinical endocrinology · 1997
The study reportedWe have shown that patients with primary hypothyroidism have higher GH responses to GHRP-6 than to GHRH, which are markedly blunted. When GHRP-6 was associated with GHRH, a significant increase in the GH response was observed in these patients, which could suggest a role for somatostatin in this process.
Different effects of growth hormone releasing peptide (GHRP-6) and GH-releasing hormone on GH release in endogenous and exogenous hypercortisolism
Borges MH et al. · Clinical endocrinology · 1997
The study reportedOur results suggest that hypercortisolism had a different effect on the GH-releasing mechanisms stimulated by GHRH and GHRP-6. Moreover, in endogenous hypercortisolism both GHRH and GHRP-6 pathways are affected, while in the exogenous group GHRP-6 releasing mechanisms are apparently preserved.
Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood
Micic D et al. · Clinical endocrinology · 1995
The study reportedThese data show that GH responses to GHRP-6 are much greater than to GHRH in late adulthood. The marked increase of plasma GH levels observed after administration of GHRP-6 alone or in combination with GHRH indicates that impaired GH secretion in late adulthood is a functional and potentially reversible state.
Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man
Frieboes RM et al. · Neuroendocrinology · 1995
The study reportedBoth GHRP and GHRH promote sleep. However, GHRP enhances stage 2 sleep and does not affect SWS.
Additional indexed literature (4)
- Preclinical · Mechanistic studyGrowth hormone releasing peptide-6 (GHRP-6) ameliorates acute lung injury and its subsequent evolvement to interstitial fibrosis
Wang L et al. · International immunopharmacology · 2026 · PMID 41534456
- Preclinical · Mechanistic studyGrowth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation
Wang L et al. · Pharmaceuticals (Basel, Switzerland) · 2026 · PMID 41901314
- Preclinical · Mechanistic studyAssessing The Effectiveness of Growth Hormone Releasing Protein-6 in Improving Human Oocyte Maturation and Meiotic Progression in In Vitro Maturation Culture Media
Ostadian C et al. · International journal of fertility & sterility · 2025 · PMID 41090425
- Preclinical · Mechanistic studyGrowth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation
Zhao X et al. · Journal of nanobiotechnology · 2025 · PMID 41327290
Published studies summarised here concern the specific investigational or pharmaceutical materials and study conditions described by their authors. Their findings are not performance claims for Cobalt Peptides material. Citations verified against PubMed on 2026-08-09.
Notice
All information on this page is provided strictly for laboratory research and educational purposes only.